SECISBP2L

Across TCGA pan-cancer cohorts, SECISBP2L RNA differs between tumor and matched normal tissue in 14 of 18 cancer types tested, making tumor–normal expression one of SECISBP2L’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where SECISBP2L RNA is repressed in tumor relative to normal tissue. In most cancer types SECISBP2L is over-expressed in tumor, although a few such as LUSC and LUAD show the opposite, repressed pattern.

LUSC, LUAD, and COAD are the cancer types where SECISBP2L tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SECISBP2L RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUSC	Female	II,III,IV	−2.012	<.001	9	view →
LUAD	Female	II,III,IV	−1.739	<.001	9	view →
COAD	Female	All	−0.971	<.001	9	view →
THCA	All	All	−0.448	.001	8	view →
UCEC	All	All	−0.995	<.001	6	view →
BRCA	Female	All	−0.483	<.001	6	view →
KIRC	All	II,III,IV	−0.408	.001	6	view →
HNSC	Male	All	−0.554	.003	5	view →
BLCA	All	All	−0.447	.025	5	view →
READ	Female	All	−1.402	<.001	2	view →
CHOL	All	All	+0.714	<.001	2	view →
KIRP	Male	All	−0.533	.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 14 lineages.

SECISBP2L–LUSC

Open the LUSC breakdown →